Changes in atherogenic lipids and lipoproteins during natural and hyperstimulated cycles in healthy women.
OBJECTIVE
To compare changes in the concentrations of Lp(a) lipoprotein and other atherogenic lipids and lipoproteins in natural and hyperstimulated ovarian cycles.


METHODS
Open, prospective study.


METHODS
Academic department in a teaching hospital.


METHODS
Normal ovulatory women served as controls and the treatment group consisted of women undergoing ovarian hyperstimulation.


METHODS
The treatment group received hMG on a fixed regimen.


METHODS
Measurements of serum lipids and lipoproteins were made in both natural and hyperstimulated cycles.


RESULTS
There was a significant increase in the median concentration of Lp(a) lipoprotein from 10.1 to 10.7 mg/dL in the luteal compared with the proliferative phase of unstimulated cycles. In hyperstimulated cycles, there was a significant increase in the median concentration of Lp(a) lipoprotein from 9.7 mg/dL in the proliferative phase to 11.3 mg/dL in the luteal phase. Reductions in concentrations of total cholesterol and low-density lipoprotein cholesterol were found in the luteal phase of hyperstimulated cycles.


CONCLUSIONS
Concentrations of Lp(a) lipoprotein increase during the luteal phase of both natural and hyperstimulated ovarian cycles.
Haines
C J
CJ
Prince of Wales Hospital, Chinese University of Hong Kong, Department of Obstetrics and Gynaecology, Shatin, New Territories, Hong Kong. CJOHNHAINES@CUHK.EDU.HK
Cheung
L P
LP
Lam
C W
CW
D000328:Adult; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005498:Follicular Phase / Q000097:blood; D006801:Humans; D008055:Lipids / Q000097:blood*; D017270:Lipoprotein(a) / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008183:Luteal Phase / Q000502:physiology; D007986:Luteinizing Hormone / Q000097:blood; D008596:Menotropins / Q000009:adverse effects / Q000627:therapeutic use; D008597:Menstrual Cycle; D010062:Ovulation Induction / Q000009:adverse effects*; D011374:Progesterone / Q000097:blood; D011446:Prospective Studies; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
D008078:Cholesterol, LDL; D008055:Lipids; D017270:Lipoprotein(a); D008074:Lipoproteins; D014280:Triglycerides; D011374:Progesterone; D004958:Estradiol; D008596:Menotropins; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone